InvestorLens

JNJ — JOHNSON & JOHNSON

Health Care · Drug Manufacturers

Sign in to save6 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying JNJ?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Strong distribution · 0 buying vs 2 selling last quarter
12
Macro Tailwind
Macro conditions are mixed for this sector
53
Congressional Activity
3 congressional purchases, 2 sales disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their JNJ position last quarter, 0 bought and 2 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 53/100 in a Overheat regime). 3 congressional purchases, 2 sales disclosed in the last 6 months.

Supporting evidence
  • +6 tracked investors reported holding JNJ at their latest filing
  • +3 congressional purchases disclosed in the last 6 months
Contradicting evidence — always shown
  • −2 tracked investors reduced or exited last quarter (2 reduced, 0 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About JOHNSON & JOHNSON (JNJ)

JOHNSON & JOHNSON (JNJ) appears in the most recent 13F filings of 6 tracked institutional investors. JOHNSON & JOHNSON is classified in the Health Care sector (Drug Manufacturers industry). The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $2.1B. Across recent filings, tracked investors recorded 4 new positions, 9 increased, 12 reduced, and 2 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in JNJ

48
/100
Mixed Activity
Added / Increased13
Reduced12
Exited2
BearishBullish
Crowded Trade Score™

How many top investors track JNJ

40
/100
Moderate Interest
6investors

Several tracked investors have exposure.

UndiscoveredCrowded
151015+

JNJ Ownership Composition

How JOHNSON & JOHNSON is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
93% of tracked value
Institutions
6
tracked investors
Total Reported
$3.5B
combined 13F value
Types2
  • Multi-Strategy / Quant93.4%
  • Macro6.6%
Multi-Strategy / Quant(3)
93.4%
Macro(3)
6.6%

Tracked investors currently reporting JNJ

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    8.4M
    Value
    $2.1B
    % Portfolio
    0.24%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    2.2M
    Value
    $549.6M
    % Portfolio
    0.20%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    2.2M
    Value
    $548.9M
    % Portfolio
    0.61%
  • Ray DalioJun 30, 2026
    Bridgewater Associates
    Shares
    669.1K
    Value
    $169.9M
    % Portfolio
    0.70%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    188.5K
    Value
    $47.9M
    % Portfolio
    0.07%
  • George SorosJun 30, 2026
    Soros Fund Management
    Shares
    34K
    Value
    $8.6M
    % Portfolio
    0.11%

Recent activity

Frequently asked questions

How many institutional investors hold JNJ?
6 tracked institutional investors disclosed a position in JNJ (JOHNSON & JOHNSON) in their most recent 13F filing.
Who is the largest institutional holder of JNJ?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in JNJ, valued at $2.1B.
Did institutional ownership of JNJ increase or decrease?
Across recent 13F filings, tracked investors recorded 4 new positions, 9 increased, 12 reduced, and 2 fully exited JNJ.
What sector is JNJ in?
JOHNSON & JOHNSON is classified in the Health Care GICS sector, Drug Manufacturers industry.
Where does this JNJ ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.